ReviewPathogens (Basel, Switzerland)2025
The Rise, Fall, and Rethink of (Fluoro)quinolones: A Quick Rundown.
Review in Pathogens (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Delafloxacin Resistance and MIC-Distribution in Ciprofloxacin-Resistant Enterobacterales: A Retrospective Evaluation of Minimum Inhibitory Concentrations.Antibiotics (Basel, Switzerland) · 2026Article
- Structure-Activity Relationship Analysis of Immunoassay Systems for (Fluoro)quinolones Detection.International journal of molecular sciences · 2026Article
- Designing the Next Generation of Antibiotics: Structure, SAR, and Strategy in Medicinal Chemistry (2000-2025).Medicinal research reviews · 2026Review
- From Antibacterial to Antifungal: Structure, Safety, and Serum Albumin Binding of Zn(II)-Nalidixate Complexes with Phenanthroline and Bipyridine.Biological trace element research · 2026Article
- Fluoroquinolone Exposure and Cancer Risk in Interstitial Lung Disease: A Propensity-Score-Matched Cohort Study Using Cox and Competing-Risk Models.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Manganese-Doped Carbon Dots for Sensitive Fluorescence Detection of Ciprofloxacin in Environmental and Pharmaceutical Samples.Biosensors · 2026Article
- Distribution and antimicrobial resistance of uropathogens: a 6-year retrospective single-center study (2019-2024).BMC infectious diseases · 2026Article
- Metabolism-Associated Hepatotoxicity of Gatifloxacin in Zebrafish Larvae.Biomolecules · 2026Article
- Symbiotic Bacterial Diversity, Functional Profiling and Antibiotic Susceptibility of the Red Imported Fire Ant.Microorganisms · 2026Article
- The role of the gut microbiome in antibiotic-driven antimicrobial resistance.Frontiers in microbiology · 2026Review
- Phage-quinolone synergy: mechanisms, clinical strategies, and translational prospects.Frontiers in microbiology · 2026Review
- Genetic Determinants and Clonal Composition of Levofloxacin-ResistantAntibiotics (Basel, Switzerland) · 2025Article
- Overexpression of the major facilitator superfamily efflux pump geneFrontiers in cellular and infection microbiology · 2025Article
- Fluoroquinolone resistance in ESKAPE pathogens: evolutionary pathways, one health transmission, and clinical surveillance.Frontiers in microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibiotics have revolutionized medicine, with (fluoro)quinolones emerging as one of the most impactful classes of antibacterial agents. Since their introduction, four generations of (fluoro)quinolones have been developed, demonstrating a broad spectrum of activity, favourable pharmacokinetics, and clinical efficacy. However, the rise of multidrug-resistant pathogens has posed significant challenges to their continued effectiveness, particularly in healthcare settings. Among the main resistant species,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.